Skip to main content

Healthy Volunteers - Male and Female

1
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Kaken Pharmaceutical
1 program
1
KP-001Phase 1
Clene
CleneSALT LAKE CITY, UT
1 program
CNM-Au8PHASE_11 trial
Active Trials
NCT02755870Completed86Est. Oct 2016
Parexel
ParexelMA - Boston
1 program
KP-001PHASE_11 trial
Active Trials
NCT06649942Completed40Est. Mar 2025
Orna Therapeutics
Orna TherapeuticsMA - Watertown
1 program
ORN252PHASE_11 trial
Active Trials
NCT07439796Recruiting20Est. Mar 2027
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
QLS7305 InjectionPHASE_12 trials
Active Trials
NCT07730632Not Yet Recruiting60Est. Aug 2028
NCT07313150Not Yet Recruiting60Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Qilu PharmaceuticalQLS7305 Injection
Orna TherapeuticsORN252
Qilu PharmaceuticalQLS7305 Injection
ParexelKP-001
CleneCNM-Au8

Clinical Trials (5)

Total enrollment: 266 patients across 5 trials

Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)

Start: Aug 2026Est. completion: Aug 202860 patients
Phase 2Not Yet Recruiting

A Study of ORN252 in Healthy Participants

Start: Mar 2026Est. completion: Mar 202720 patients
Phase 1Recruiting

A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults

Start: Jan 2026Est. completion: Dec 202760 patients
Phase 1Not Yet Recruiting

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

Start: Oct 2024Est. completion: Mar 202540 patients
Phase 1Completed

A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers

Start: Apr 2015Est. completion: Oct 201686 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 266 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.